From Obesity to Diabetes

Herausgegeben:Eckel, Juergen; Clément, Karine

• Gebundenes Buch

Produktbeschreibung

Obesity is a major risk factor for the development of type 2 diabetes and its associated complications, a major socio-economic burden for health care systems. The worldwide prevalence of obesity doubled since 1980 and as a consequence the number of patients with diabetes has been continuously rising with more than 450 Mio. people suffering from this disease at the present time. Substantial progress has been made in understanding the molecular pathways leading from excessive fat accumulation to metabolic perturbation and finally diabetes manifestation. This edition of the "Handbook of Experimental Pharmacology" aims to analyze new insight into the pathophysiology of obesity, to decipher the complex links to diabetes and its complications, and to collect most recent information on new strategies for prevention and treatment of obesity and diabetes.

Produktdetails

• Handbook of Experimental Pharmacology 274
• Verlag: Springer / Springer International Publishing / Springer, Berlin
• Artikelnr. des Verlages: 978-3-030-99994-0
• 1st ed. 2022
• Seitenzahl: 524
• Erscheinungstermin: 22. Juli 2022
• Englisch
• Abmessung: 241mm x 160mm x 32mm
• Gewicht: 1041g
• ISBN-13: 9783030999940
• ISBN-10: 3030999947
• Artikelnr.: 63531935

Inhaltsangabe

Part I Obesity. Epidemiology of Obesity.- The Circadian Clock and Obesity.- Nutrition and Microbiome.- From Obesity to Diabetes: The Role of the Adipose Organ.- Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy.- The Enteroendocrine System in Obesity.- Insights from Studies of White Adipose Tissue Using Single-Cell Approaches.- Obesity-Related Insulin Resistance: The Central Role of Adipose Tissue Dysfunction.- Obesity, Senescence, and Senolytics.- Obesity and Obstructive Sleep Apnea.- Part II Diabetes and Complications. Inter-Organ Crosstalk in the Development of Obesity-Associated Insulin Resistance.- Islet Inflammation and beta Cell Dysfunction in Type 2 Diabetes.- NAFLD and NASH: The Metabolically Diseased Liver.- Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities.- Diabetic Peripheral Neuropathy.- Part III Lifestyle Modifications and Future Treatments. Weight Loss Strategies.- PhysicalActivity, Obesity and Weight Loss Maintenance.- Bariatric/Metabolic Surgery.- Drugs for Treating Obesity.- Novel Drugs for Diabetes Therapy.- Novel Approaches to Restore Pancreatic Beta-Cell Mass
and Function.- Precision Medicine and Obesity.- Targeting the Enteroendocrine System for Treatment of Obesity.

---

Part I Obesity. Epidemiology of Obesity.- The Circadian Clock and Obesity.- Nutrition and Microbiome.- From Obesity to Diabetes: The Role of the Adipose Organ.- Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy.- The Enteroendocrine System in Obesity.- Insights from Studies of White Adipose Tissue Using Single-Cell Approaches.- Obesity-Related Insulin Resistance: The Central Role of Adipose Tissue Dysfunction.- Obesity, Senescence, and Senolytics.- Obesity and Obstructive Sleep Apnea.- Part II Diabetes and Complications. Inter-Organ Crosstalk in the Development of Obesity-Associated Insulin Resistance.- Islet Inflammation and β Cell Dysfunction in Type 2 Diabetes.- NAFLD and NASH: The Metabolically Diseased Liver.- Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities.- Diabetic Peripheral Neuropathy.- Part III Lifestyle Modifications and Future Treatments. Weight Loss Strategies.- PhysicalActivity, Obesity and Weight Loss Maintenance.- Bariatric/Metabolic Surgery.- Drugs for Treating Obesity.- Novel Drugs for Diabetes Therapy.- Novel Approaches to Restore Pancreatic Beta-Cell Mass
and Function.- Precision Medicine and Obesity.- Targeting the Enteroendocrine System for Treatment of Obesity.